Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective
Authors:
- Philip J. MeasePMPhilip J. Mease
- M. Alan MenterMMM. Alan Menter
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (4) , 685-704
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Decision points for the initiation of systemic treatment for psoriasisJournal of the American Academy of Dermatology, 2005
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- Spirituality, well‐being, and quality of life in people with rheumatoid arthritisArthritis Care & Research, 2003
- Development and use of alefacept to treat psoriasisJournal of the American Academy of Dermatology, 2003
- Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque PsoriasisDermatology, 2003
- Quality of life measures: use and abuseBest Practice & Research Clinical Rheumatology, 2000
- The Application of Multiple Quality-of-Life Instruments in Individuals with Mild-to-Moderate PsoriasisPharmacoEconomics, 1996
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995
- Genital Tumors among Men with Psoriasis Exposed to Psoralens and Ultraviolet A Radiation (PUVA) and Ultraviolet B RadiationNew England Journal of Medicine, 1990
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980